07:00 , Feb 28, 2018 |  BioCentury  |  Finance

Repairing resistance

While Novo Nordisk Foundation has funded antimicrobial resistance research for years, the foundation’s investment arm, Novo Holdings A/S, is taking that mandate a step further with its first fund dedicated to early stage venture in...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Adenium Biotech management update

Adenium Biotech ApS, Copenhagen, Denmark   Business: Infectious   Hired: Edward Fang as CMO, formerly director of clinical sciences at Trius Therapeutics Inc., which Cubist Pharmaceuticals Inc. acquired   ...
07:00 , Oct 21, 2013 |  BioCentury  |  Emerging Company Profile

Adenium: Lugworms vs. superbugs

Adenium Biotech ApS is developing derivatives of arenicin-3 to create a safer antibiotic than colistin to treat infections caused by multidrug-resistant Gram-negative pathogens. Colistin is a broad-spectrum Gram-negative antibacterial first introduced in 1952. It was replaced...